Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01672775 | A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology | completed | Phase 1 | 34 | Agensys, Inc.INDUSTRY | 2 | Nov 1, 2024 | clinicaltrials |
| NCT03246074 | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | completed | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 24, 2024 |
| clinicaltrials |
| NCT03776968 | A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics | completed | Phase 1 | 47 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04978675 | An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06566989 | A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) | completed | Phase 1 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT03596281 | Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer(PEMBOV) | completed | Phase 1 | 47 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06648902 | Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue | completed | Phase 1 / Phase 2 | 60 | Kidney Cancer Research BureauOTHER | 3 | Oct 18, 2024 | clinicaltrials |
| NCT06554639 | A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) | completed | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT02555397 | Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer | completed | Phase 1 | 15 | Henry Ford Health SystemOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04060394 | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | completed | Phase 1 / Phase 2 | 49 | Laekna LimitedINDUSTRY | 2 | Oct 10, 2024 | clinicaltrials |
| NCT02667886 | Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 74 | X4 PharmaceuticalsINDUSTRY | 2 | Oct 3, 2024 | clinicaltrials |
| NCT01774071 | Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT02480374 | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer | completed | Phase 1 | 18 | ImunonINDUSTRY | 1 | Oct 2, 2024 | clinicaltrials |
| NCT04713891 | A Study of KF-0210 in Advanced Solid Tumors Patients | completed | Phase 1 | 14 | Keythera Pharmaceuticals (Australia) Pty LtdINDUSTRY | 1 | Sep 24, 2024 | clinicaltrials |
| NCT02903771 | Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. | completed | Phase 1 | 32 | Kazia Therapeutics LimitedINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT03532451 | Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer(PrE0807) | completed | Phase 1 | 43 | PrECOG, LLC.OTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03558711 | PSMA-PET/CT for Prostate Cancer(NGP1) | completed | Phase 1 | 6 | University Hospital, GhentOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02324582 | MK-3475/BCG in High Risk Superficial Bladder Cancer(MARC) | completed | Phase 1 | 18 | Southern Illinois UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT02566772 | Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 | 130 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 3, 2024 | clinicaltrials |
| NCT04548193 | Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship | completed | Phase 1 | 49 | Roswell Park Cancer InstituteOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05362955 | 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa | completed | Phase 1 | 12 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03539406 | Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients(INTRO) | completed | Phase 1 | 11 | Radboud University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03206177 | Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | completed | Phase 1 | 26 | University of OklahomaOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT01685268 | A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | completed | Phase 1 / Phase 2 | 49 | Astex Pharmaceuticals, Inc.INDUSTRY | 4 | Aug 2, 2024 | clinicaltrials |
| NCT03154281 | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | completed | Phase 1 | 14 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06517433 | First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 62 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06517485 | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 142 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 48 | Compugen LtdINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT02344095 | A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer(POPOPO) | completed | Phase 1 | 12 | Seoul National University HospitalOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT04701021 | TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy | completed | Phase 1 | 12 | Ultimovacs ASAINDUSTRY | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03200587 | Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) | completed | Phase 1 | 12 | University of UtahOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03829111 | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | completed | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT05578820 | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | completed | Phase 1 | 21 | Gene Surgery LLCINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT02808143 | Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer | completed | Phase 1 | 9 | Northwestern UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT01326871 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | completed | Phase 1 / Phase 2 | 68 | Altor BioScienceINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04284761 | A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer(Biolen-PC) | completed | Phase 1 | 17 | Alessa Therapeutics Inc.INDUSTRY | 3 | Jun 24, 2024 | clinicaltrials |
| NCT03276572 | Phase I Trial of 225Ac-J591 in Patients With mCRPC | completed | Phase 1 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT00194714 | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | completed | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 1, 2024source: clinicaltrials